Form 4: Guardant Health CPO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 8,571 shares of common stock for approximately $977,440 through a pre-arranged 10b5-1 plan.
Summary
- Terilyn J. Monroe, the Chief People Officer of Guardant Health, Inc. (GH), sold a total of 8,571 shares of the company's common stock.
- The transactions took place on January 21, 2026, as part of a pre-arranged Rule 10b5-1(c) trading plan.
- The shares were sold in three separate transactions at weighted average prices of $112.3418, $113.4793, and $115.6978 per share.
- The total proceeds from these sales amounted to approximately $977,439.98.
- Following these reported transactions, Terilyn J. Monroe beneficially owns 20,990 shares of Guardant Health common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine insider transaction conducted under a pre-arranged 10b5-1 plan, which is a common practice for executive liquidity and diversification.
Positives
- The sale was executed under a Rule 10b5-1 trading plan, which indicates the transaction was pre-scheduled and not based on immediate, non-public information.
Negatives
- The sale by a Chief People Officer reduces the direct equity ownership of a key executive in the company.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The reported transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 01/21/2026 | This indicates a pre-planned and compliant approach to insider trading, enhancing transparency and mitigating concerns about opportunistic trading. |
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in direct executive ownership, which is generally not a significant concern when conducted under a 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 01/21/2026 | Date of common stock transactions by Terilyn J. Monroe. |
| 01/22/2026 | Date the Form 4 was signed by attorney-in-fact for Terilyn J. Monroe. |
Keywords
Guardant Health, GH, Insider Transaction, Stock Sale, Form 4, Terilyn J. Monroe, Chief People Officer, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.